CAMP4 Therapeutics Receives EU Approval for Phase 1/2 Clinical Trial of CMP-002

Article summary

CAMP4 Therapeutics has received approval for its Clinical Trial Application to initiate a Phase 1/2 study of CMP-002 for patients with SYNGAP1-related disorder in the European Union.